Fourth formoterol/budesonide dry powder inhaler launched

WockAIR is a breath-actuated dry powder inhaler available in two strengths, providing formoterol/budesonide delivered doses of 4.5/160 microgram and 9/320 microgram. It is bioequivalent to Symbicort Turbohaler (based on 80–125% bioequivalence limits for AUC, Cmax, and standard flow parameters).

Sustainable option

WockAIR is indicated in adults and adolescents from 12 years for the regular treatment of asthma, where the combination of an inhaled corticosteroid (ICS) and a long-acting β2 adrenoceptor agonist (LABA) is appropriate. This includes patients not adequately controlled with ICS and 'as needed' inhaled short-acting β2 adrenoceptor agonists, and patients already adequately controlled on both ICS and LABA.

WockAIR 4.5/160 microgram can be used for asthma maintenance and reliever therapy, where it is taken both as regular maintenance treatment and as needed in response to symptoms. WockAIR 9/320 microgram is licensed only for maintenance therapy.

Both strengths of WockAIR are also indicated in adults 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

As a dry powder inhaler, WockAIR has a lower carbon footprint than pressurised metered dose inhalers (MDIs). MDIs have estimated carbon footprints of 500g CO₂eq per dose, compared to 20g in dry powder inhalers, according to NICE. A patient decision aid published by NICE in 2019 recommends that prescribers and patients opt for the most environmentally friendly option when faced with a choice of suitable devices.